Graft Versus Tumor (gvt) Effect - Pharma

Relevant Publications

Graft-versus-tumor effect of post-transplant cyclophosphamide-based allogeneic hematopoietic cell transplantation.

Issue Release: 2024

GM-CSF in Allogenic Hematopoietic Stem Cell Transplantation: from Graft-versus-Host Disease to Graft-versus-Tumor effect.

Issue Release: 2024

Thrombin receptor activating peptide-6 decreases acute graft-versus-host disease through activating GPR15.

Issue Release: 2024

Sustained remission after cord blood transplantation for breast cancer with lung metastases and myelodysplastic syndrome.

Issue Release: 2024

TIM-3 blockade enhances ex vivo stimulated allogeneic NK cell therapy for relapsed murine neuroblastoma after hematopoietic cell transplant.

Issue Release: 2024

Harnessing allogeneic CD4 T cells to reinvigorate host endogenous antitumor immunity.

Issue Release: 2023

Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.

Issue Release: 2023

Magnesium enhances the graft-versus-tumor effect of donor lymphocytic infusion on hematologic malignancies.

Issue Release: 2023

CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma.

Issue Release: 2023

Pembrolizumab for the treatment of disease relapse following allogeneic hematopoietic stem cell transplantation.

Issue Release: 2022

Editorial on Translational Research in Graft-Versus-Host Disease (GVHD) and Graft-Versus-Tumor (GVT) Effect After Allogeneic Hematopoietic Cell Transplantation.

Issue Release: 2022

CT-098 Impact of T-Cell Dose on Outcome of T Cell-Replete HLA-Mismatched Allogeneic Peripheral Blood Stem Cell Transplantation.

Issue Release: 2022

Analysis of T cell Repertoire and Transcriptome Identifies Mechanisms of Regulatory T cell (Treg) Suppression of GvHD.

Issue Release: 2022

Immunoregulatory effects of RGMb in gut inflammation.

Issue Release: 2022

Graft-Versus-Solid-Tumor Effect: From Hematopoietic Stem Cell Transplantation to Adoptive Cell Therapies.

Issue Release: 2022

ICOS immunoPET enables visualization of activated T cells and early diagnosis of murine acute gastrointestinal GvHD.

Issue Release: 2022

Blockade of PD-1/PD-L1 increases effector T cells and aggravates murine chronic graft-versus-host disease.

Issue Release: 2022

Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation.

Issue Release: 2021

Combining Immunocytokine and Activated NK Cells as a Platform for Enhancing Graft-Versus-Tumor Effects Against GD2 Murine Neuroblastoma.

Issue Release: 2021

MyD88 Costimulation in Donor CD8 T Cells Enhances the Graft-versus-Tumor Effect in Murine Hematopoietic Cell Transplantation.

Issue Release: 2021

What Role Does Regulatory Affairs Play?

What Are the Challenges in Managing Chronic Conditions?

Who are Pharmacists?

What is a New Drug Application (NDA)?

What is Pharma?

What Strategies do Brand-Name Companies Use to Delay Generic Entry?

Why is Medication Management Important?

How Can Pharmacists Contribute to Transitional Care?

What are the Implications for Pharma Companies?

What are Adverse Drug Events?

Partnered Content Networks

Relevant Topics